Preclinical and clinical development of palbociclib and future perspectives
- 586 Downloads
Cyclin-dependent kinases (CDKs) play a key role in cell cycle regulation, which makes them a clear therapeutic target to interfere with cell division and proliferation in cancer patients. Palbociclib, a specific inhibitor of CDK4/6 with outstanding clinical efficacy data and limited toxicity, has been recently approved for the treatment of hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, either in combination with an aromatase inhibitor or in combination with fulvestrant in women who have received prior endocrine therapy. This review describes the mechanism of action, preclinical experiences and clinical data of palbociclib, with a special focus on integrating this data with the positioning of palbociclib in the current clinical guidelines for advanced HR-positive/HER2-negative breast cancer. Aspects of the ongoing major studies are also presented, as well as future prospects in the development of palbociclib.
KeywordsCyclin Cell cycle Anti-tumor Breast cancer PI3K Palbociclib Cyclin-dependent kinases CDK4/6
The authors wish to thank Dr. Fernando Sánchez-Barbero from HealthCo S.L. (Madrid, Spain) for his help in the preparation of the manuscript. Pfizer provided comment on the first draft of this manuscript, but thereafter authors made all the decisions about its contents.
Pfizer provided the financial support of medical writing services.
Compliance with ethical standards
Conflict of interest
The authors declare that they do not have any conflict of interest that may inappropriately influence this work.
The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.(FDA) USFDAUS. Palbociclib (IBRANCE). 2017. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm549978.htm. Accessed 30 June 2017.
- 3.(EMA) EMA. Ibrance (palbociclib). 2017. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003853/human_med_002034.jsp&mid=WC0b01ac058001d124. Accessed 30 June 2017.
- 9.Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Clark A, O’Dwyer P, Troxel A, Lal P, Feldman M, Gallagher M, et al. Abstract P6-13-08: palbociclib and paclitaxel on an alternating schedule for advanced breast cancer: results of a phase Ib trial. Cancer Res. 2016;76:P6-13-08-P6-13-08.Google Scholar
- 21.Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18:568–76.CrossRefPubMedGoogle Scholar
- 23.Finn RS, Hurvitz S, Allison M, Applebaum S, Glaspy J, DiCarlo B et al. Phase I study of PD 0332991, a novel, oral, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole, for first-line treatment of metastatic post-menopausal, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Cancer Res. 2009;69(24 Suppl):5069.Google Scholar
- 24.Finn RS, Dieras V, Rugo HS, Joy AA, Moulder SL, Walshe JM, Mukai H, Shparyk YV. Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): efficacy and safety across patient (pt) subgroups. J Clin Oncol. 2017;35(suppl; abstr 1039). https://meetinglibrary.asco.org/recd/152804/abstract.
- 25.Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.CrossRefPubMedGoogle Scholar
- 29.Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev. 2003;CD002747. https://doi.org/10.1002/14651858.CD002747.
- 30.Robertson JFR, Paridaens R, Bogaerts J, Rukazenkov Y, Campbell C, Bradbury I. Visceral metastases from hormone receptor positive breast cancer are as sensitive to endocrine therapy as non-visceral metastases. Cancer Res. 2015;75(9):P1-13-02.Google Scholar